License and Agreements (Details) - USD ($)	1 Months Ended				3 Months Ended
	May 31, 2020	Jan. 31, 2020	Jan. 20, 2020	Jan. 31, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 24, 2019	Mar. 31, 2018
License and Agreements (Details) [Line Items]
Assignment fee									$ 100,000
Milestone fee								$ 50,000
Common shares outstanding price percentage								1.00%
Payments of shares		$ 50,000
Research and development costs					$ 5,278,252	$ 2,235,542
Accounts payable due					108,000		$ 59,000
Research and development expense					494,000	341,000
Pre-marketing approvals					25,000,000
Master Services [Member]
License and Agreements (Details) [Line Items]
Assignment fee					685,000		56,000
Agreement term, description				In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.
Research and development costs					1,812,000	$ 779,000
Q-Pharm Pty Ltd [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					0		$ 0
master consultancy agreement with Novotech (Australia) Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Agreement description			to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$83,000 (US$63,000) and AUD$170,000 (US$131,000) as of March 31, 2021 and December 31, 2020, respectively. During the three months ended March 31, 2021 and 2020, the Company recorded research and development costs of approximately AUD$705,000 (US$545,000) and AUD$85,000 (US$56,000), respectively, pertaining to this agreement.
clinical trial research agreement with Nucleus Network Pty Ltd.[Member]
License and Agreements (Details) [Line Items]
Agreement description	to provide a Phase I study of one of the Company’s drug candidates, Tacrolimus. The accounts payable due in connection with this agreement was approximately AUD$21,000 (US$16,000) and AUD$51,000 (US$40,000) as of March 31, 2021 and December 31, 2020, respectively. During the three months ended March 31, 2021, the Company recorded research and development costs of approximately AUD$244,000 (US$188,000), pertaining to this agreement.
Master Services Agreement [Member]
License and Agreements (Details) [Line Items]
Research and development costs					196,000
Accounts payable due					$ 9,000